Sino Biopharmaceutical Limited, a China-based pharmaceutical company, and global drugmaker Sanofi on Wednesday announced an exclusive global licensing agreement for Rovaciditinib, a JAK/ROCK dual-target inhibitor.
Under the agreement, Sino Biopharma and its subsidiary Chia Tai Tianqing Pharmaceutical will grant Sanofi exclusive global rights to develop, manufacture and commercialize the product, in...
